Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2)

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 2023 Aug 14

PMID 37578463

Authors

Zonghui Ma

Andrew A Bolinger

Haiying Chen

Jia Zhou

Affiliations

Soon will be listed here.

Abstract

Nuclear receptor binding SET domain proteins (NSDs) catalyze the mono- or dimethylation of histone 3 lysine 36 (H3K36me1 and H3K36me2), using -adenosyl-l-methionine (SAM) as a methyl donor. As a key member of the NSD family of proteins, NSD2 plays an important role in the pathogenesis and progression of various diseases such as cancers, inflammations, and infectious diseases, serving as a promising drug target. Developing potent and specific NSD2 inhibitors may provide potential novel therapeutics. Several NSD2 inhibitors and degraders have been discovered while remaining in the early stage of drug development. Excitingly, KTX-1001, a selective NSD2 inhibitor, has entered clinical trials. In this Perspective, the structures and functions of NSD2, its roles in various human diseases, and the recent advances in drug discovery strategies targeting NSD2 have been summarized. The challenges, opportunities, and future directions for developing NSD2 inhibitors and degraders are also discussed.

Citing Articles

Emerging regulatory mechanisms and functions of biomolecular condensates: implications for therapeutic targets.

Jeon S, Jeon Y, Lim J, Kim Y, Cha B, Kim W Signal Transduct Target Ther. 2025; 10(1):4.

PMID: 39757214 PMC: 11701242. DOI: 10.1038/s41392-024-02070-1.

The oncogenic role of the NSD histone methyltransferases in head and neck and cervical cancers.

Ghiani L, Chiocca S Tumour Virus Res. 2024; 19:200301.

PMID: 39645166 PMC: 11683330. DOI: 10.1016/j.tvr.2024.200301.

Identification of potential methyltransferase NSD2 enzymatic inhibitors through a multi-step structure-based drug design.

Shen Y, Zhang Y, Wu T, Zhang L, Belviso B Mol Divers. 2024; .

PMID: 39644397 DOI: 10.1007/s11030-024-11072-8.

Epigenetics-targeted drugs: current paradigms and future challenges.

Dai W, Qiao X, Fang Y, Guo R, Bai P, Liu S Signal Transduct Target Ther. 2024; 9(1):332.

PMID: 39592582 PMC: 11627502. DOI: 10.1038/s41392-024-02039-0.

Unveiling the potential of phytochemicals to inhibit nuclear receptor binding SET domain protein 2 for cancer: Pharmacophore screening, molecular docking, ADME properties, and molecular dynamics simulation investigations.

Mohamed G, Abdallah H, Sindi I, Ibrahim S, Alzain A PLoS One. 2024; 19(8):e0308913.

PMID: 39163297 PMC: 11335128. DOI: 10.1371/journal.pone.0308913.

References

Li M, Zhi Y, Liu B, Yao Q . Advancing Strategies for Proteolysis-Targeting Chimera Design. J Med Chem. 2023; 66(4):2308-2329. DOI: 10.1021/acs.jmedchem.2c01555. View

Bottcher J, Dilworth D, Reiser U, Neumuller R, Schleicher M, Petronczki M . Fragment-based discovery of a chemical probe for the PWWP1 domain of NSD3. Nat Chem Biol. 2019; 15(8):822-829. DOI: 10.1038/s41589-019-0310-x. View

Hyun K, Jeon J, Park K, Kim J . Writing, erasing and reading histone lysine methylations. Exp Mol Med. 2017; 49(4):e324. PMC: 6130214. DOI: 10.1038/emm.2017.11. View

Belkina A, Denis G . BET domain co-regulators in obesity, inflammation and cancer. Nat Rev Cancer. 2012; 12(7):465-77. PMC: 3934568. DOI: 10.1038/nrc3256. View

Cao C, He M, Wang L, He Y, Rao Y . Chemistries of bifunctional PROTAC degraders. Chem Soc Rev. 2022; 51(16):7066-7114. DOI: 10.1039/d2cs00220e. View

Ma Z, Bolinger A, Zhou J, Tian B . Bromodomain-containing protein 4 (BRD4): a key player in inflammatory bowel disease and potential to inspire epigenetic therapeutics. Expert Opin Ther Targets. 2023; 27(1):1-7. PMC: 11092387. DOI: 10.1080/14728222.2023.2175317. View

Zhou P, Wu L, Wu K, Jiang W, Li J, Zhou L . Overexpression of MMSET is correlation with poor prognosis in hepatocellular carcinoma. Pathol Oncol Res. 2012; 19(2):303-9. DOI: 10.1007/s12253-012-9583-z. View

Crews C, Georg G, Wang S . Inducing Protein Degradation as a Therapeutic Strategy. J Med Chem. 2016; 59(11):5129-30. DOI: 10.1021/acs.jmedchem.6b00735. View

Wagner E, Nath N, Flemming R, Feltenberger J, Denu J . Identification and characterization of small molecule inhibitors of a plant homeodomain finger. Biochemistry. 2012; 51(41):8293-306. PMC: 3567257. DOI: 10.1021/bi3009278. View

10.

Umit Kaniskan H, Martini M, Jin J . Inhibitors of Protein Methyltransferases and Demethylases. Chem Rev. 2017; 118(3):989-1068. PMC: 5610952. DOI: 10.1021/acs.chemrev.6b00801. View

11.

Matta-Camacho E, Kozlov G, Li F, Gehring K . Structural basis of substrate recognition and specificity in the N-end rule pathway. Nat Struct Mol Biol. 2010; 17(10):1182-7. DOI: 10.1038/nsmb.1894. View

12.

Qin S, Min J . Structure and function of the nucleosome-binding PWWP domain. Trends Biochem Sci. 2014; 39(11):536-47. DOI: 10.1016/j.tibs.2014.09.001. View

13.

Saloura V, Vougiouklakis T, Zewde M, Deng X, Kiyotani K, Park J . WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer. Sci Rep. 2017; 7:40664. PMC: 5244396. DOI: 10.1038/srep40664. View

14.

Ishida T, Ciulli A . E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones. SLAS Discov. 2020; 26(4):484-502. PMC: 8013866. DOI: 10.1177/2472555220965528. View

15.

Nimura K, Ura K, Shiratori H, Ikawa M, Okabe M, Schwartz R . A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome. Nature. 2009; 460(7252):287-91. DOI: 10.1038/nature08086. View

16.

Swaroop A, Oyer J, Will C, Huang X, Yu W, Troche C . An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia. Oncogene. 2018; 38(5):671-686. PMC: 6358490. DOI: 10.1038/s41388-018-0474-y. View

17.

Bachmair A, Finley D, Varshavsky A . In vivo half-life of a protein is a function of its amino-terminal residue. Science. 1986; 234(4773):179-86. DOI: 10.1126/science.3018930. View

18.

Gao B, Liu X, Li Z, Zhao L, Pan Y . Overexpression of EZH2/NSD2 Histone Methyltransferase Axis Predicts Poor Prognosis and Accelerates Tumor Progression in Triple-Negative Breast Cancer. Front Oncol. 2021; 10:600514. PMC: 7921704. DOI: 10.3389/fonc.2020.600514. View

19.

di Luccio E, Koehl P . A quality metric for homology modeling: the H-factor. BMC Bioinformatics. 2011; 12:48. PMC: 3213331. DOI: 10.1186/1471-2105-12-48. View

20.

Landgren O, Graubard B, Katzmann J, Kyle R, Ahmadizadeh I, Clark R . Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia. 2014; 28(7):1537-42. PMC: 4090286. DOI: 10.1038/leu.2014.34. View